PURPOSE. To screen for and characterize compounds that protect corneal endothelial cells against unfolded protein response (UPR) and oxidative stress.
F uchs' endothelial corneal dystrophy (FECD) is a common cause of corneal vision loss characterized by corneal endothelial (CE) cell loss and abnormalities in Descemet membrane. [1] [2] [3] Early disease stages are asymptomatic, but in the disease course corneal edema and loss of vision occur approximately 20 years after onset. 4 Fuchs' endothelial corneal dystrophy is among the leading causes of primary corneal transplant surgery in Europe and the United States, and so far there is no definitive conservative (nonsurgical) treatment. 5 Evidence of oxidative stress in the pathogenesis of FECD has been described. 6, 7 Unfolded protein response (UPR) activation leads to endothelial cell apoptosis in Fuchs' dystrophy and may play a central pathogenic role in this disease. 8, 9 Koh and Waschek 10 have described the survival effects of vasoactive intestinal peptide for cultured corneal endothelial cells undergoing oxidative stress with H 2 O 2 . High-throughput screening (HTS) is being used more commonly to identify novel therapeutic compounds. 11 Given the previous evidence for endoplasmic reticulum (ER) and oxidative stress in the pathogenesis of FECD, we sought to develop an efficient system to screen a commercially available drug library of Food and Drug Administration (FDA)-approved drugs for improved survival of cultured corneal endothelial cells undergoing ER and oxidative stress. Positive drugs were further tested for doseresponse effects and alterations in ER and oxidative stress specific markers.
The approach described in the present work identified mefenamic acid as a drug with positive and specific survival effects against ER and oxidative stress in cultured corneal endothelial cells. This method could be extended to identify drugs with similar effects on known or yet to be elucidated pathophysiologic mechanisms in corneal endothelial diseases.
The overall purpose of this study was to apply a rational approach to drug discovery/screening, which could yield additional agents with the potential to alter the disease course and form the basis of nonsurgical treatments for these disorders.
METHODS Cell Culture
Primary cultures of bovine corneal endothelial cells (BCECs) from freshly enucleated globes were established by scraping Descemet membrane of excised corneas with a surgical blade and resuspending cells in Dulbecco's modification of Eagle's minimum essential medium (DMEM; Cellgro, Manassas, VA, USA) supplemented with 10% fetal calf serum, antibiotic/ antimycotic solution (10,000 units of penicillin [base], 10,000 lg of streptomycin [base] , and 25 lg of amphotericin B/mL; Invitrogen, Grand Island, NY, USA) and 50 lg/mL of gentamicin (Invitrogen). Cells were maintained at 378C with 5% CO 2 in air on a 6-well plate (Cytoone, Orlando, FL, USA). Once confluence was reached (usually 7-10 days), the primary cultures were subcultured to 96-well plates (Cytoone) in the same medium.
Immortalized 
Dose Response Assays
After initial selection of drugs with medium to high levels of protection (grade 2-3), additional dose response assays were performed with BCECs to determine the effective dose range for each protective drug and to determine the efficacy of an optimal dose of drug against oxidative stress and UPR. The following drugs were tested (all from Sigma-Aldrich Corp.): oxotremorine, mefenamic acid, nimesulide, and diclofenac. Each drug was resuspended in DMSO at a stock concentration of 10 mM and diluted in cell culture medium. Oxotremorine, mefenamic acid, and nimesulide were retested in quadruplicate at 0.0-, 0. 
Real-Time PCR
Immortalized HCECs cultured in triplicate 6-well plates were pretreated with 50.0-lM oxotremorine, 20.0-lM mefenamic acid, or no drug (only 0.5% and 0.2% DMSO, respectively) for 48 hours followed by treatment with thapsigargin (2.5 lM) for 24 hours at 378C in a humidified 5% CO 2 atmosphere. RNA samples were extracted from iHCECs with TRIzol (Ambion, Austin, TX, USA) using the RNAeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. A 100-ng quantity of RNA was reverse transcribed using a High Capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA, USA). Real time-PCR was performed using the TaqMan Gene Expression Master Mix (23; Applied Biosystems), preamplified cDNA products (diluted 1:20; 5 uL), nuclease free water, and human-specific primers (Supplementary Table S1 ; Applied Biosystems) in a 20-lL reaction volume. A no-template control was included in each experiment to confirm the absence of DNA contamination. All assays used similar amplification efficiency, and a DC T experimental design was used for relative quantification. Data analysis was performed using StepOne software (Version 2.2; Applied Biosystems). Data were normalized to GAPDH and are expressed as relative expression compared with cells untreated with thapsigargin, oxotremorine, or mefenamic acid.
Western Blot
Immortalized HCECs cultured in triplicate 6-well plates were pretreated with 50.0-lM oxotremorine, 20.0-lM mefenamic acid, or no drug for 48 hours followed by treatment with thapsigargin (2.5 lM) for 24 hours at 378C in a humidified 5% CO 2 atmosphere. Cells were lysed with ice-cold Tissue Protein Extraction Reagent (Thermo Fisher Scientific) containing protease inhibitor (1%) and EDTA (1%). Total protein concentration was measured using a protein assay kit (Thermo Fisher Scientific) and each sample was adjusted to 20 lg/mL. Proteins were subjected to SDS-PAGE (Mini-PROTEAN TGX Gels; Bio-Rad, Hercules, CA, USA) and transferred to polyvinvlidene fluoride membranes (The PerfectMembrane; GenHunter Corporation, Nashville, TN, USA) that had been soaked in methanol for 1 minute. After blocking with 5% milk for 1 hour, the membranes were then incubated overnight with rabbit anti-ATF4 antibody (1:1000 dilution; Cell Signaling Technology, Danvers, MA, USA), or rabbit anti-GRP78 antibody (1:1000; Cell Signaling Technology). The membranes were then incubated with horseradish peroxidase-conjugated donkey anti-rabbit IgG antibodies (1:10,000 dilution; Cell Signaling Technology) for 30 minutes. The membrane was washed with tris buffered saline with Tween 20 (TBST; Cell Signaling Technology) and antigen was detected using ECL solution (Pierce Biotechnology, Inc., Rockford, IL, USA). Membranes were stripped with Restore Western blotting stripping buffer (Thermo Fisher Scientific) using manufacturer's instructions, reblocked with 5% milk for 1 hour, and restained for GAPDH using rabbit anti-GAPDH antibody (HRP conjugate, 1:10000; Cell Signaling Technology) with 1-hour incubation at room temperature.
ELISA of Oxidative Stress Markers
Immortalized HCECs cultured in triplicate 6-well plates were pretreated with 50.0-lM oxotremorine, 20.0-lM mefenamic acid, or no drug for 48 hours followed by treatment with H 2 O 2 (0.8 mM) for 4 hours at 378C in a humidified 5% CO 2 atmosphere. Protein carbonyls and 8-hydroxydeoxyguanosine (8-OHdG) were evaluated as oxidative stress markers. Protein carbonyls in iHCECs were measured using ELISA (OxiSelect Protein Carbonyl ELISA Kit; Cell Biolabs, San Diego, CA, USA) according to the manufacturer's protocols. Treated cells were lysed with ice-cold Tissue Protein Extraction Reagent (Thermo Fisher Scientific) containing protease inhibitor (1%) and EDTA (1%). Total protein concentration was measured using a protein assay kit (Thermo Fisher Scientific) and each sample was diluted to 10 lg/mL. 8-OHdG in iHCECs was measured by DNA extraction (QIAamp DNA Mini Kit; Qiagen) followed by ELISA (OxiSelect Oxidative DNA Damage ELISA Kit; Cell Biolabs).
Statistical Analysis
Statistical analysis was performed with two-tailed Student's ttest using SPSS (version 16.0; IBM, Armonk, NY, USA) or JMP (version 10.0.2; SAS, Cary, NC, USA) and P less than 0.05 was considered statistically significant.
RESULTS

Preliminary Cytotoxic Assay
Cytotoxic effects of BCECs exposed to H 2 O 2 for 4 hours and thapsigargin for 24 hours showed a dose-dependent response. The LD50 values for H 2 O 2 and thapsigargin against BCECs were 0.6 mM and 25.6 lM, respectively (Supplementary Figs. S1A, S1B). In a similar way, the LD50s for H 2 O 2 and thapsigargin against iHCECs were 0.18 mM and 16.5 lM (data not shown). 
Initial Screen
Bovine corneal endothelial cells were used in this screening test. For a flow chart of the initial screening process (Fig. 1) . Initial screening of the 640 drug library using conditions established by the preliminary cytotoxic assay demonstrated 55 drugs at 100 lM and 41 at 20 lM with moderate to high levels of increased cell survival (grade 2-3) against H 2 O 2 conditioning. Against thapsigargin conditioning, two drugs at 100 lM and eight at 20 lM demonstrated moderate to high levels of increased cell survival. Overall, 14 drugs demonstrated increased cell survival with both concentrations of drug tested showing a grade 2 to 3 effect against either oxidative stress or UPR (Supplementary Table S2 ). Five drugs (ergothioneine, nicergoline, nimesulide, mefenamic acid, and oxotremorine) were found to demonstrate a grade 2 to 3 survival effect at one concentration against both oxidative stress and UPR (Supplementary Table S2 ).
Dose Response Assays
After initial screening of the FDA drug library, dose-response assays with BCECs were performed for the five compounds with survival effects against both of oxidative stress and UPR. Nicergoline and ergothioneine did not exhibit a clear response (data not shown), but oxotremorine, mefenamic acid, and nimesulide exhibited a significant dose response. Cell viability of 0.3-(75.2 6 14.1%, P ¼ 0.002), 1.0-(80.8 6 4.0%, P ¼ Cell viability of 0.3-(69.1 6 2.0%, P ¼ 0.02), 1.0-(71.2 6 8.2%, P ¼ 0.01), 3.0-(73.6 6 8.7%, P ¼ 0.01), 10.0-(73.2 6 3.5%, P ¼ 0.005), and 30.0-lM (68.7 6 3.4%, P ¼ 0.03) mefenamic acid-treated cells against oxidative stress was significantly increased compared with 0.0-lM control (60.8 6 6.0%; Fig. 3A ). Cell viability of 10.0-(57.4 6 2.4%, P ¼ 0.04) and 30.0-lM (61.7 6 3.1%, P ¼ 0.04) mefenamic acid-treated cells against UPR was significantly increased compared with 0.0-lM control (51.9 6 3.7%; Fig. 3B) . Overall, mefenamic acid demonstrated a maximal effect at 3.0 lM of 21.1% increased cell viability against H 2 O 2 and a maximal effect at 30.0 lM of 18.9% increased cell viability against thapsigargin.
Cell viability of 1.0-(47.0 6 3.3%, P ¼ 0.01) and 3.0-lM (51.3 6 3.8%, P ¼ 0.001) nimesulide-treated cells against oxidative stress was significantly increased compared with 0.0-lM control (41.9 6 1.5%; Fig. 4A ). Cell viability of 1.0-(57.0 6 Based on the above results indicating a protective effect of the nonsteroidal anti-inflammatory drugs (NSAIDs) mefenamic acid and nimesulide on BCECs exposed to oxidative stress and UPR, we selected diclofenac, a highly potent NSAID 13 for additional dose-response testing. Cell viability of 0.3-(60.1 6 5.2%, P ¼ 0.01) and 1.0-lM (61.6 6 4.4%, P ¼ 0.005) diclofenac-treated cells against oxidative stress was significantly increased compared with 0.0-lM control (52.1 6 2.7%; Fig.  5A ). However, cell viability of 3.0-(51.5 6 3.4%, P ¼ 0.01), 10.0-(50.6 6 4.6%, P ¼ 0.02), 30.0-(50.0 6 4.7%, P ¼ 0.01), 100.0-(45.2 6 2.9%, P ¼ 0.0005), and 300.0-lM (43.4 6 4.2%, P ¼ 0.0007) diclofenac-treated cells against UPR was significantly decreased compared with 0.0-lM control (57.8 6 3.1%; Fig. 5B ). Overall diclofenac demonstrated a maximal effect at 1.0 lM of 18.2% increased cell viability against H 2 O 2 and a maximal effect at 300 lM of 24.9% decreased cell viability against thapsigargin.
In addition, we sought to characterize potential cell protective effects of oxotremorine and mefenamic acid on HCECs using iHCECs. Cell viability of 60.0-lM (78.4 6 7.3%, P ¼ 0.0002) oxotremorine-treated cells against oxidative stress was significantly increased compared with 0.0-lM control (40.9 6 6.3%; 
Effects of Oxotremorine and Mefenamic Acid on UPR Markers
To assess mRNA level effects of oxotremorine and mefenamic acid on UPR markers in HCECs, iHCECs were pretreated with 50.0-lM oxotremorine or 20.0-lM mefenamic acid, exposed to thapsigargin, and real-time PCR was performed for ATF4 and CHOP (Supplementary Table S1 ), two commonly used markers of UPR. 14, 15 For thapsigargin-exposed iHCECs, oxotremorine treatment showed a trend for reduced ATF4 mRNA expression to 118.2 6 43.7% (P ¼ 0.23) compared with untreated controls (148.3 6 28.3%) and reduced CHOP mRNA expression to 112.3 6 60.6% (P ¼ 0.024) compared with untreated controls (188.1 6 8.0%; Fig. 7A ). For thapsigargin-exposed iHCECs, mefenamic acid treatment showed trends for reduced ATF4 mRNA expression to 117.0 6 13.6% (P ¼ 0.10) compared with untreated controls (135.6 6 18.1%) and reduced CHOP mRNA expression to 170.9 6 19.7% (P ¼ 0.06) compared with untreated controls (190.9 6 6.5%; Fig. 7B) .
To assess protein level effects of oxotremorine and mefenamic acid on UPR markers in HCECs, iHCECs were pretreated with 50.0-lM oxotremorine or 20.0-lM mefenamic acid, exposed to thapsigargin, and Western blot was performed for ATF4 and GRP78, which are also commonly used markers of UPR. 14, 15 For thapsigargin-exposed iHCECs, oxotremorine treatment increased GRP78 protein expression to 894.6 6 123.7% (P ¼ 0.013) compared with untreated controls (462.6 6 121.9%) and decreased ATF4 protein expression to 3943.6 6 307.7% (P ¼ 0.039) compared with untreated controls 6465.3 6 1413.3% (Fig. 8A) . For thapsigargin-exposed iHCECs, mefenamic acid treatment increased GRP78 protein expression to 455.0 6 154.9% (P ¼ 0.038) compared with untreated controls (168.0 6 52.7%) and showed a trend for decreased ATF4 protein expression to 19354.7 6 10697.4% (P ¼ 0.44) compared with untreated controls (27061.5 6 11133.2%; Fig.  8B ).
Effects of Oxotremorine and Mefenamic Acid on Oxidative Stress Markers
To assess effects of oxotremorine and mefenamic acid on oxidative stress in HCECs, iHCECs were pretreated with 50.0-lM oxotremorine or 20.0-lM mefenamic acid, exposed to H 2 O 2 , and protein carbonyl and 8-OHdG levels were measured by ELISA. For H 2 O 2 -exposed iHCECs, mefenamic acid treatment reduced protein carbonyl levels to 90.7 6 7.1% (P ¼ 0.037), and oxotremorine treatment reduced protein carbonyl levels to 83.8 6 10.7% (P ¼ 0.028) compared with untreated controls (131.5 6 21.9%; Fig. 9A ). For H 2 O 2 -exposed iHCECs, mefenamic acid treatment reduced 8-OHdG levels to 173.3 6 15.7% (P ¼ 0.0008), and oxotremorine treatment reduced 8-OHdG levels to 175.0 6 31.2% (P ¼ 0.0051) compared with untreated controls (275.0 6 21.2%; Fig. 9B ).
DISCUSSION
Fuchs' endothelial corneal dystrophy results from primary loss of corneal endothelial cells and is a common cause of corneal vision loss. Current definitive therapy includes endothelial keratoplasty, and there is no nonsurgical treatment to delay or prevent disease progression. Multiple studies using keratoplasty tissue have shown evidence of oxidative stress in FECD. 6, 7 We have shown evidence of unfolded protein response activation in FECD patient corneas and in a mouse model of FECD. 8, 9 Thus, we sought to develop a system to screen for drugs with corneal endothelial cell survival effects against oxidative stress and UPR. The link between oxidative stress and UPR has been established in multiple reports. Holtz et al. described oxidative stress-triggered UPR in cell death evoked by Parkinson mimetics. Tumor necrosis factor-alpha has been shown to induce UPR in a reactive oxygen species (ROS) dependent fashion. 17 Tagawa et al. 18 demonstrated endoplasmic reticulum (ER) stress-mediated apoptosis is induced by cigarette smoke via an ROS-dependent mechanism. 19 Our results demonstrate a dose response effect of the muscarinic receptor agonist, oxotremorine, and the NSAIDs, mefenamic acid and nimesulide, against oxidative stress and UPR in a BCEC culture model. Although bovine cells are commonly used in studies of the corneal endothelium, [20] [21] [22] their use is a potential shortcoming of our system. However, our previous experience with primary cultured human corneal endothelium [23] [24] [25] indicated potential difficulties obtaining adequate numbers of phenotypically consistent cells for the high throughput scale of these experiments. Thus, we used immortalized corneal endothelial cells 12 to confirm doseresponsive survival and further characterize the effects of oxotremorine and mefenamic acid against ER and oxidative stress in human cells. Another potential shortcoming of our system is the use of pretreatment with pharmacologic agents prior to the application of cellular stress. We chose this design expecting it to maximize effects on cell survival. However, clinical situations would likely include the possibility of initiating drug therapy in patients with moderate to advanced disease (i.e., after intermediate to severe levels of cell stress were already established). Thus, follow-up studies in cultured HCECs with pre-and post-stress application of candidate drugs are warranted prior to drawing further implications in diseases such as FECD. A further shortcoming of our work involves short-term responses to relatively high doses of cytotoxic agents. Such a model, though convenient for high throughput analysis, may have limited relevance to FECD, which more likely involves lower levels of chronic cellular stress.
Stimulation of muscarinic receptors provides substantial protection from DNA damage, oxidative stress, and mitochondrial impairment. 26 Oxotremorine prevents camptothecininduced mitochondrial cytochrome c release, Bcl-2 depletion, and Bax accumulation. 26 In addition, activation of muscarinic receptors blocks caspase 3 activation. 27 The mechanism by which oxotremorine increases survival of cultured corneal endothelial cells treated with the UPR inducer, thapsigargin, is not well understood. Thapsigargin blocks the ability of the cell to pump calcium into the ER, which results in ER damage. 28 Oxotremorine has also been shown to cause an increase in intracellular free Ca 2þ . 29 Thus, one could speculate that oxotremorine would synergize with thapsigargin to cause increased cytotoxicity mediated by intracellular calcium levels. This result was not observed in our cell survival data for reasons yet to be elucidated.
Mefenamic acid decreases production of the free radical nitric oxide and reduces cytochrome c release from mitochondria induced by Ab 1-42 , Swe-APP, or APP-CTs in neuronal cells. 30 Similarly, our results show significantly decreased oxidative stress markers in mefenamic acid-treated iHCECs exposed to H 2 O 2 . Thus, our results indicate, for the first time to our knowledge, the ability of mefenamic acid to upregulate the UPR marker GRP78 and to alleviate cytotoxicity caused by the UPR inducer, thapsigargin.
COX-2 inhibitors such as nimesulide act as antioxidants to correct lipid peroxidation products such as malondialdehyde (MDA). 31 Unfolded protein response due either to expression of viral surface proteins or drugs can stimulate the expression of COX-2 through the nuclear factor kappa-B and pp38 kinase pathways. 32 Thus, NSAIDs may represent an attractive agent to reduce both oxidative stress and UPR in corneal cells in vivo. Additional NSAIDs in our drug library showed a partial protective effect against either H 2 O 2 (celecoxib, diclofenac, fenoprofen, ketoprofen, niflumic acid, piroxicam, and tolfenamic acid) or thapsigargin (aceclofenac). Diclofenac was selected as a potent NSAID for additional follow-up studies in our ER and oxidative stress model system. 13 Our results indicate positive cell survival effects against oxidative stress, but decreased survival against UPR (Fig. 5) . Diclofenac previously has been shown to reduce superoxide and peroxide production as well as to reduce glutathione depletion in human lens epithelial cells exposed to oxidative stress. 13 However, diclofenac also activates the PERK pathway of the UPR, which induces the expression of the proapoptotic GADD153/CHOP. 33 Thus, our results indicate differential effects of individual NSAIDs on the responses to ER versus oxidative stress in corneal endothelial cells.
Chiu et al. 34 recently used a high throughput assay system and elegant mechanistic studies to identify the NSAID, glafenine, as being able to reduce retention of SLC4A11 mutant protein in the ER and increase post-ER trafficking to the cell membrane. Properly trafficked mutant SLC4A11 was further shown to retain partial function. 34 These authors suggested that prostaglandin synthesis may contribute to ER retention of mutant proteins, and a further inference of this work would be that NSAIDs could reduce UPR levels for certain misfolded mutant proteins. Our work using a high throughput drug library screen to identify the positive survival effects of multiple NSAIDS (Supplementary Table S2 ) against the UPR inducer thapsigargin supports these earlier findings by Chiu et al. 34 To our knowledge, this is the first system for screening drugs with corneal endothelial cell survival effect against ER and oxidative stress. Based on our results, it is tempting to speculate that NSAIDs such as mefenamic acid, nimesulide, or others may have potential efficacy as a survival factor for corneal endothelial cells under these stressors in vivo. Our screening system also could be used as the basis of an expanded approach to identify additional therapeutic targets for corneal endothelial diseases.
